<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2837">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02196116</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2013/02</org_study_id>
    <nct_id>NCT02196116</nct_id>
  </id_info>
  <brief_title>Amyloïd Load in Elderly Population: Effect of Cognitive Reserve</brief_title>
  <acronym>EDUMA</acronym>
  <official_title>Amyloïd Load in Elderly Population: Effect of Cognitive Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Plan Alzheimer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research aim to explore relationships between the presence of amyloid burden and&#xD;
      cognitive performance, and its modulation by educational level. For this purpose we will&#xD;
      combine Positron emission tomography (PET) imaging and neuropsychological assessment acquired&#xD;
      on 3 groups of subjects, from two population-based cohorts &quot;3C&quot; and &quot;AMIMage&quot; The first group&#xD;
      includes cognitively intact participants who will serve as controls, the second group,&#xD;
      subjects with mild cognitive impairments without memory complaint and the third, subjects&#xD;
      with both mild cognitive impairments and memory complaint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influence of educational level on the relationship between disease-specific lesion&#xD;
      development and cognitive function will be assessed, as measured by amyloid PET imaging and a&#xD;
      battery of neuropsychological tests at the very early stages of the disease, comparatively to&#xD;
      age-matched controls. In addition, this project will explore the influence of cognitive&#xD;
      complaint.&#xD;
&#xD;
      It's assumed that 1) the amyloid-PET measures in age-matched controls and subjects from the&#xD;
      two cohorts will correlate with cognitive performances; 2) the amyloid burden will be higher&#xD;
      in high- than in low-educated subjects with similar cognitive impairment; and 3) similarly&#xD;
      the amyloid burden will be higher in subjects with cognitive complaint compared to subjects&#xD;
      without cognitive complaint.&#xD;
&#xD;
      Considering a longer term, the clinical follow-up of study participants will allow to&#xD;
      investigate the prognosis value of amyloid load for improving the prediction of cognitive&#xD;
      decline and disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amyloid load</measure>
    <time_frame>at inclusion (day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological scores</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Educational level</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory complaint</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Plaque, Amyloid</condition>
  <condition>Cognitive Deficits</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively-impaired subjects without dementia and without memory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively-impaired subjects without dementia and with memory</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET</intervention_name>
    <description>PET Scan with [18F]-Flutemetamol</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychological tests</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participation in the AMI or 3C cohorts Group 1- Controls&#xD;
&#xD;
          -  MMSE &gt; 24 or &gt; 26 for low and high levels of education, respectively.&#xD;
&#xD;
          -  Without memory impairment (for episodic memory) on the Free and Cued Selective&#xD;
             Reminding Test RL/RI-16 items (FCSRT), free recall &gt; 22 and total recall &gt;42,&#xD;
             according to the thresholds for population-based studies&#xD;
&#xD;
          -  Without memory complaint&#xD;
&#xD;
          -  Without dementia Group 2- Cognitively-impaired subjects without dementia and without&#xD;
             memory complaints&#xD;
&#xD;
          -  Mini Mental State Evaluation (MMSE) &lt; 24 or &lt; 26 for low and high levels of education,&#xD;
             respectively&#xD;
&#xD;
          -  With memory impairments according to the RL/RI-16 test (free recall≤22 and/or total&#xD;
             recall ≤42), according to the thresholds for population-based studies defined by&#xD;
             Auriacombe et al., 2010.&#xD;
&#xD;
          -  Without memory complaint&#xD;
&#xD;
          -  Without dementia Group 3- Cognitively-impaired subjects without dementia and with&#xD;
             memory complaints&#xD;
&#xD;
          -  MMSE &lt; 24 or &lt; 26 for low and high levels of education, respectively&#xD;
&#xD;
          -  With memory impairments according to the RL/RI-16 test (same thresholds as above)&#xD;
&#xD;
          -  With memory complaint&#xD;
&#xD;
          -  Without dementia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being left handed&#xD;
&#xD;
          -  Presence of dementia (based on the clinical diagnosis)&#xD;
&#xD;
          -  Presence of stroke&#xD;
&#xD;
          -  Presence of Parkinson's disease&#xD;
&#xD;
          -  Presence of a counter-indication for MRI&#xD;
&#xD;
          -  Presence of a counter-indication for PET Scan with [18F]-Flutemetamol&#xD;
&#xD;
          -  Presence of any health problem preventing travel to the imaging service of the&#xD;
             University Hospital&#xD;
&#xD;
          -  Being under the legal guardianship of another person or being unable to provide&#xD;
             consent to participate&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michèle ALLARD, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michèle ALLARD, MD-PhD</last_name>
    <email>Michele.allard@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline BUISSON, CRA</last_name>
    <email>caroline.buisson@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele ALLARD, MD</last_name>
      <email>michele.allard@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Michèle ALLARD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François DARTIGUES, Md, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe FERNANDEZ, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Simon ARNOULD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri De CLERMONT GALLERANDE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo ZANOTTI FREGONARA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Igor SIBON, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra FOUBERT, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer disease</keyword>
  <keyword>amyloid load</keyword>
  <keyword>educational level</keyword>
  <keyword>cognitive performances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Plaque, Amyloid</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

